Previous reports have shown that treatment with the AChE inhibitor, donepezil, was associated with increased serum BDNF levels in AD patients suggesting that AChE inhibitors act to increase BDNF levels leading to neuroprotective effects [48]. Here, ACHE is linked to Alzheimer disease.